Based on its unique properties, SVac is ideally suited for developing next generation effective gene and immune therapies. In order to realize our ambition to become the leading global gene therapy company, they formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology, and gene therapy fields of research. With major regulatory, legal, and intellectual property firms, they are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies, and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of society in general.